Effects of Rosuvastatin Combined with Ticagrelor on Serum Endothelin-1 and Tissue Plasminogen Activator Levels in Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

HUANG Lingfang; DI Ningning; SHEN Xun; ZHOU Song

doi:10.14009/j.issn.1672-2124.2020.02.019

您当前的位置：

首页 >

文章列表页 >

Effects of Rosuvastatin Combined with Ticagrelor on Serum Endothelin-1 and Tissue Plasminogen Activator Levels in Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention

更新时间：2022-10-08

- Effects of Rosuvastatin Combined with Ticagrelor on Serum Endothelin-1 and Tissue Plasminogen Activator Levels in Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
- Vol. 20, Issue 2, Pages: 200-203(2020)
- 作者机构：
  
  邢台市第三医院心内二科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.02.019
  CLC： R542.22
- Published：2020，
扫描看全文
[1]黄玲芳,狄宁宁,申恂,周松.瑞舒伐他汀与替格瑞洛联合应用对行经皮冠状动脉介入治疗的急性ST段抬高型心肌梗死患者血清内皮素-1、组织型纤溶酶原激活物水平的影响[J].中国医院用药评价与分析,2020,20(02):200-203.

HUANG Lingfang, DI Ningning, SHEN Xun, et al. Effects of Rosuvastatin Combined with Ticagrelor on Serum Endothelin-1 and Tissue Plasminogen Activator Levels in Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. [J]. 20(2):200-203(2020)
[1]黄玲芳,狄宁宁,申恂,周松.瑞舒伐他汀与替格瑞洛联合应用对行经皮冠状动脉介入治疗的急性ST段抬高型心肌梗死患者血清内皮素-1、组织型纤溶酶原激活物水平的影响[J].中国医院用药评价与分析,2020,20(02):200-203. DOI： 10.14009/j.issn.1672-2124.2020.02.019.

HUANG Lingfang, DI Ningning, SHEN Xun, et al. Effects of Rosuvastatin Combined with Ticagrelor on Serum Endothelin-1 and Tissue Plasminogen Activator Levels in Patients with Acute ST-segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. [J]. 20(2):200-203(2020) DOI： 10.14009/j.issn.1672-2124.2020.02.019.

摘要

目的:探讨瑞舒伐他汀与替格瑞洛联合应用对行经皮冠状动脉介入治疗（percutaneous coronary intervention

PCI）的急性ST段抬高型心肌梗死（ST-segment elevation myocardial infarction

STEMI）患者血清内皮素-1（ET-1）、组织型纤溶酶原激活物（t PA）水平的影响。方法:选取2017年6月至2018年6月邢台市第三医院收治的120例急性STEMI患者

以随机数字表法分为对照组和观察组

每组60例。两组患者均予以阿司匹林+替格瑞洛抗血小板治疗

并行PCI术;在此基础上

对照组患者加用阿托伐他汀治疗

观察组患者加用瑞舒伐他汀治疗。观察两组患者的血脂指标[总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）及三酰甘油（TG）]、肱动脉内皮依赖性舒张功能（FMD）以及血清ET-1、t PA水平

比较不良反应发生情况。结果:治疗后

两组患者的TC、LDL-C及TG水平均较治疗前明显降低

且观察组患者的TC、LDL-C水平明显低于对照组

差异均有统计学意义（P<0. 05）;两组患者的FMD均较治疗前明显升高

且观察组患者明显高于对照组

差异均有统计学意义（P<0. 05）;两组患者血清ET-1水平均较治疗前明显降低

t PA水平均较治疗前明显升高

且观察组患者血清ET-1水平明显低于对照组

t PA水平明显高于对照组

上述差异均有统计学意义（P<0. 05）。观察组、对照组患者的不良反应发生率分别为3. 33%（2/60）、5. 00%（3/60）

差异无统计学意义（P>0. 05）。结论:瑞舒伐他汀与替格瑞洛联合用于行PCI术的急性STEMI患者

能够有效调节血脂

改善血管内皮功能

降低ET-1水平

提高t-PA水平

且安全性较高。

Abstract

OBJECTIVE: To probe into the effects of rosuvastatin combined with ticagrelor on serum endothelin-1（ ET-1） and tissue plasminogen activator（ t PA） levels in patients with acute ST-segment elevation myocardial infarction（ STEMI） undergoing percutaneous coronary intervention（ PCI）. METHODS: Totally 120 patients with acute STEMI admitted into Xingtai Third Hospital from Jun. 2017 to Jun. 2018 were extracted to be divided into the control group and the observation group via the random number table

with 60 cases in each group. Both groups were treated with aspirin +tigrello antiplatelet therapy and PCI. On this basis

the control group was treated with atorvastatin

while the observation group received rosuvastatin. Blood lipid indicators [total cholesterol（ TC）

low density lipoprotein cholesterol（ LDL-C）

and triacylglycerol（ TG） ]

flow-mediated vasodilation（ FMD） and serum ET-1 and t PA levels of two groups were observed

and the incidence of adverse drug reactions in two groups were compared. RESULTS: After treatment

the levels of TC

LDL-C and TG in two groups were significantly lower than those before treatment

and the levels of TC and LDL-C in the observation group were significantly lower than those in the control group

with statistically significant differences（ P < 0. 05）. The FMD level of two groups was significantly higher than that before treatment

and the observation group was significantly higher than the control group

with statistically significant differences（ P<0. 05）. The serum ET-1 level in both groups was significantly lower than that before treatment

and the t PA level was significantly higher than that before treatment; meanwhile

the serum ET-1 level in the observation group was significantly lower than that in the control group

and the t PA level was significantly higher than that in the control group

with statistically significant differences（ P<0. 05）. The incidence of adverse drug reactions in the observation group and the control group was 3. 33%（ 2/60） and 5. 00%（ 3/60）

respectively

with no significant difference（ P> 0. 05）. CONCLUSIONS:Rosuvastatin combined with ticagrelor for acute STEMI patients undergoing PCI can effectively regulate blood lipids

improve vascular endothelial function

reduce ET-1 levels and increase t-PA levels

with higher safety.

关键词

急性ST段抬高型心肌梗死瑞舒伐他汀血脂血管内皮功能内皮素-1组织型纤溶酶原激活物

Keywords

Acute ST-segment elevation myocardial infarctionRosuvastatinBlood lipidVascular endothelial functionEndothelin-1Tissue plasminogen activator

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-Analysis of Efficacy and Safety of Ticagrelor Combined with Rosuvastatin Therapy in the Treatment of Unstable Angina Pectoris

Effects of Huangqi Guizhi Wuwu Decoction on Heart Rate Recovery from Bradyarrhythmia,Serum Fatty Acid Binding Protein Levels and Plasma Ang Ⅱ,Adropin and Gal-3

Effects of Modified Banxia Baizhu Tianma Decoction on CGRP, ET-1, Blood Viscosity and Cerebral Blood Flow Velocity in Patients with Posterior Circulation Ischemic Vertigo （Phlegm Stasis and Blocking Collaterals Type）

Effect of Dangua Humai Oral Liquid on Vascular Endothelial Function and Oxidative Stress Indicators in Patients with Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease

Related Author

YANG Juan

LI Ruyou

HE Wei

CUI Jie

FAN Zongjing

WU Yang

ZHANG Chen

LUO Ruixiang

Related Institution

Dept.of Geriatrics, Edong Healthcare Group Huangshi Central Hospital/Affiliated Hospital of Hubei Polytechnic University

Dept.of Respiratory Medicine, Edong Healthcare Group Huangshi Central Hospital/Affiliated Hospital of Hubei Polytechnic University

Dept.of Endocrine, the Second People’s Hospital of Yichang

North District Branch,Beijing Emergency Medical Center

School of Clinical Medicine, Beijing University of Traditional Chinese Medicine

⁰